Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery
NCT ID: NCT06904248
Last Updated: 2025-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
224 participants
INTERVENTIONAL
2024-01-29
2025-02-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy, Safety and Tolerability Study of Meloxicam Injection in Subjects After Abdominal Surgery
NCT05950152
A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery
NCT06890533
A Phase Ⅱ Study to Evaluate the Efficacy and Safety of YZJ-4729 in Patients With Moderate to Severe Acute Pain After Abdominal Surgery
NCT06680466
Multimodal Analgesia in Shoulder Arthroplasty
NCT03586934
HR021618 in Moderate to Severe Pain After Abdominal Surgery
NCT04811053
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Meloxicam Injection
Meloxicam Injection
Intravenous meloxicam Injection, 30mg every 24 hours, for a total of 2 doses
Placebo
Sodium Chloride Injection
Intravenous Sodium Chloride Injection, 18mg every 24 hours, for a total of 2 doses
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Meloxicam Injection
Intravenous meloxicam Injection, 30mg every 24 hours, for a total of 2 doses
Sodium Chloride Injection
Intravenous Sodium Chloride Injection, 18mg every 24 hours, for a total of 2 doses
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Be scheduled to undergo abdominal surgery under general anesthesia with anticipated moderate to severe postoperative pain.
3. Be American Society of Anesthesiology (ASA) physical class 1 or 2.
4. Be able to understand the pain intensity evaluation methods.
5. 18kg/m\^2\<body mass index ≤30 kg/m\^2.
6. Female Participants must not be pregnant or lactating. Participants(including their partners)must agree to use appropriate contraception from the time of signing the informed consent form until 3 months after the last dose.No plans for sperm or egg donation during the study period.
7. Be able to understand the study purpose and procedures, agree to participate in the study program, Voluntarily provide written informed consent.
Exclusion Criteria
2. Have a history or clinical manifestations of significant cerebrovascular, respiratory, renal, hepatic, endocrine, neurological, psychiatric systemic diseases, or advanced malignant tumors, and judged by the investigator as unsuitable for participation in this study.
3. Have a history of migraine, anxiety,seizures, cognitive dysfunction, or other psychiatric or neurological disorders that the investigator believes may interfere with the study evaluation.
4. Participants with the following cardiovascular diseases or history:
1. Severe cardiovascular diseases, NYHA heart function class II or above, myocardial infarction, angina, or coronary artery bypass grafting (CABG) within the preceding 12 months, severe arrhythmias, or abnormal ECG during the screening period judged by the investigator as unsuitable for participation in this study.
2. Resting systolic blood pressure ≥160mmHg in a sitting or lying position, and/or diastolic blood pressure ≥100mmHg during the screening period, from the signing of the informed consent to before anesthesia induction.
3. Clinically significant respiratory insufficiency, hypotension, bradycardia occurring intraoperatively or postoperatively before randomization, judged by the investigator as unsuitable for participation in this study.
5. Have another painful physical condition judged by the investigator that may confound the assessments of post operative pain.
6. Have (within 12 months) gastrointestinal ulceration, erforation, gastrointestinal bleeding, or abdominal surgery before the screening period judged by the investigator as unsuitable for participation in this study.
7. Have a known bleeding disorder or be taking agents affecting coagulation judged by the investigator as unsuitable for participation in this study.
8. Participants at high risk of bleeding, including those with congenital bleeding disorders (e.g., hemophilia), thrombocytopenia (platelet count below 0.75× the lower limit of normal), or abnormal platelet function (e.g., idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, congenital platelet dysfunction).
9. ALT or AST \>2 ULN, TBIL \>1.5 ULN, PT \>ULN+3s, APTT ≥ULN+10s, Cr ≥1.5×ULN during the screening period, or any laboratory abnormalities judged by the investigator at screening and/or before surgery that may increase the risk of participation.
10. Blood glucose ≥11.1mmol/L from the screening period to before anesthesia induction.
11. Use of the following drugs (not exceeding 5 half-lives of the drug) before randomization, except for anesthetics and sedative/analgesic drugs used preoperatively for invasive examinations as allowed by the protocol: NSAIDs (including compound preparations containing NSAIDs), opioids, anesthetics, sedatives, hypnotics, anticonvulsants, antipsychotics, other central nervous system inhibitors with analgesic effects, and glucocorticoids (excluding topical and inhaled medications).
12. Use traditional Chinese medicines or proprietary Chinese medicines that could interfere with the evaluation of efficacy or safety judged by the investigator.
13. Have been receiving or have received opioid therapy defined Long-term use (continuous use ≥3 days) of opioid analgesics within 14 days before the screening period.
14. Have a history of alcohol abuse (regularly drinks \> 14 units of alcohol per day: 1 unit = 360mL beer or 45mL of 40 % spirits or 150mL wine) within the past 2 years or a history of acute alcohol intoxication, alcohol dependence, drug abuse.
15. Have received any drug/device clinical trials within 3 months before dosing with study medication.
16. Have other conditions that make the subject unsuitable for participation in the clinical study in the opinion of the investigator.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yangtze River Pharmaceutical Group Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cangzhou People's Hospital
Cangzhou, , China
The Third Xiangya Hospital Of Central South University
Changsha, , China
Heping Hospital Affiliated To Changzhi Medical College
Changzhi, , China
Sichuan Academy of Medical Sciengces & Sichuan Provincial People's Hospital
Chengdu, , China
The Second People's Hospital Of Chengdu
Chengdu, , China
The Third People's Hospital Of Chengdu
Chengdu, , China
The First People's Hospital Of Guangyuan
Guangyuan, , China
The First affiliated Hospital Of Jinan University
Guangzhou, , China
The Affiliated Hospital Of Guizhou Medical University
Guizhou, , China
Haikou People's Hospital
Haikou, , China
The Second Hospital Of Anhui Medical University
Hefei, , China
The First Affiliated Hospital Of University Of South ChinaThe First Affiliated Hospital Of University Of South China
Hengyang, , China
Meihekou Central Hospital
Meihekou, , China
Nanjing Women and Children's Healthcare Hospital
Nanjing, , China
The Second Nanning People's Hospital
Nanning, , China
Ningbo Medical Center Lihuili Hospital
Ningbo, , China
The Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, , China
The First Affiliated Hospital Of Xi'an Medical University
Xi'an, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YZJ-MLXK-YZ-2208
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.